Related Experiment Video
Updated: Sep 9, 2025
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs
Huibo Li1,2, Yumiao Pan1,3, Wenzheng Liu4
1Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Immune checkpoint inhibitors (ICIs) can cause severe immune-related colitis (ir-colitis). Early detection and multidisciplinary management, including corticosteroids, are crucial for effective treatment of this ICI side effect.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Immune checkpoint inhibitors (ICIs) represent a breakthrough in cancer therapy, but immune-related adverse events (irAEs) pose clinical challenges.
- Immune-related colitis (ir-colitis) is a serious gastrointestinal irAE that requires prompt recognition and management.
Observation:
- A case of grade 3 ir-colitis induced by sintilimab (a PD-1 inhibitor) in a patient with endometrial cancer is presented.
- The patient experienced severe diarrhea, progressing despite initial treatments, necessitating a multidisciplinary team (MDT) approach.
Findings:
- High-dose corticosteroid therapy led to significant clinical improvement in the patient with sintilimab-induced ir-colitis.
- The report elucidates the link between PD-1 blockade and ir-colitis pathogenesis, emphasizing mucosal immune dysregulation.
Implications:
- This case underscores the importance of early diagnosis, patient education, and MDT collaboration for managing ICI-induced ir-colitis.
- Understanding the mechanisms of ir-colitis can optimize therapeutic outcomes and advance cancer immunotherapy.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...